A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to test the safety of an experimental drug called RMC-6291 or RMC-6236 in combination with pembrolizumab in non-small cell lung cancer (NSCLC). Both study drugs, RMC-6236 and RMC-6291, has not been approved by the Food and Drug Administration (FDA). Pembrolizumab is FDA approved but not in combination with RMC- 6291 or RMC-6236. You will be assigned to receive RMC-6291 in combination with pembrolizumab if you have an advanced cancer which has a mutation in a gene known as KRAS^G12C. You will be assigned to receive RMC-6236 in combination with pembrolizumab if you have an advanced cancer which has a mutation in a gene known as RAS. The study will test the safety of the study drugs at different doses in combination with a fixed dose of pembrolizumab, either with or without chemotherapy, and how your body processes this combination.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Must have life expectancy of at least 3 months - No major surgery within 28 days of start on study drug and sufficiently recovered from a surgical procedure